SCHLIEREN/ZURICH, Switzerland, May 19, 2026
Mabylon AG announced positive preliminary Phase Ia clinical data for its lead investigational therapy MY006, a multi-specific antibody designed to prevent severe allergic reactions in patients with peanut allergy. The company also confirmed the initiation of the Phase Ib patient portion of the ongoing study following a recommendation from the independent Safety Monitoring Committee (SMC). The update represents a major milestone for Mabylon as it advances a new generation of long-acting antibody therapies targeting severe allergic diseases with potentially fewer yearly treatments compared with conventional allergy management approaches.
The ongoing first-in-human Phase Ia/Ib study is a randomized, quadruple-blinded, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary clinical activity of MY006 in healthy volunteers and peanut-allergic adolescents and adults. According to Mabylon, dosing in healthy volunteers has now been completed across all cohorts in Part A of the study. Preliminary blinded data showed that MY006 has been generally well tolerated, with no treatment-related serious adverse events or severe adverse events reported to date. In addition, the therapy demonstrated pharmacokinetic characteristics consistent with Mabylon’s predictive models, including linear dose proportionality and an extended half-life, supporting its potential as a long-acting prophylactic therapy.
MY006 Designed as Long-Acting Preventive Peanut Allergy Therapy
MY006 is being developed as a subcutaneous multi-specific antibody treatment capable of neutralizing multiple peanut allergens simultaneously. The therapy is designed to prevent allergic reactions, including potentially life-threatening anaphylaxis, through only a few injections per year. Peanut allergy remains one of the most dangerous and persistent food allergies worldwide, with accidental exposure posing substantial health risks and limited preventive treatment options currently available.
Based on the favorable safety and PK findings observed during the healthy volunteer portion of the trial, the study’s Safety Monitoring Committee approved progression into Part B, which evaluates MY006 in peanut-allergic patients. Mabylon confirmed that the first patients entered screening in early May 2026. The patient portion of the study will investigate early signs of clinical activity and desensitization potential using double-blinded, placebo-controlled food challenges conducted at multiple timepoints after administration of MY006.
Dr. Niccolò Pengo, Chief Scientific Officer of Mabylon, stated that the initiation of the patient portion of the study represents an important milestone for the company and supports confidence in MY006 as a differentiated prophylactic treatment strategy for peanut allergy. The company believes the extended half-life profile of MY006 may allow for durable allergen protection while reducing treatment burden for patients.
Advertisement
Mabylon Expands Pipeline With MY010 Tree Pollen Allergy Program
Alongside progress with MY006, Mabylon also announced advancement of its second clinical development program, MY010, targeting tree pollen allergies associated with the Fagales order. The investigational multi-specific antibody is designed to neutralize allergens from birch pollen as well as related tree pollens including oak, hazel, and alder. The company reported that MY010 recently completed cell line development and has entered GMP manufacturing ahead of GLP toxicology studies and future IND-enabling activities.
Mabylon additionally confirmed the formation of a dedicated Clinical Development Advisory Board for MY010, bringing together specialists in allergy and immunology to guide the program’s future development. The company stated that funding secured from its approximately CHF 30 million financing round completed in 2025 will support advancement of both MY006 and MY010 through upcoming development stages.
Human-Derived Multi-Specific Antibody Platform Targets Allergic Diseases
Mabylon is developing a platform of human-derived, half-life extended multi-specific antibodies targeting allergies, inflammation, and neurodegenerative diseases. The company believes patient-derived antibodies may provide therapeutic advantages compared with antibodies generated from conventional engineered systems. Its platform focuses on identifying disease-relevant allergenic epitopes and designing therapies capable of simultaneously neutralizing several clinically important allergens.
According to CEO Dr. Alcide Barberis, Mabylon’s broader strategy is to establish a leading pipeline of antibody-based therapies addressing severe allergic diseases through long-acting, differentiated biologics. The company stated that the progress of both MY006 and MY010 demonstrates the scalability and potential versatility of its multi-specific antibody platform.
If future clinical studies confirm efficacy and long-term protection, MY006 could emerge as a next-generation biologic therapy for peanut allergy management, potentially transforming preventive treatment strategies for patients at risk of severe allergic reactions.
Source: Mabylon AG press release
